Cheri A. Pasch

904 total citations
31 papers, 397 citations indexed

About

Cheri A. Pasch is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Cheri A. Pasch has authored 31 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 11 papers in Cancer Research and 10 papers in Molecular Biology. Recurrent topics in Cheri A. Pasch's work include Cancer Cells and Metastasis (12 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Cancer Genomics and Diagnostics (5 papers). Cheri A. Pasch is often cited by papers focused on Cancer Cells and Metastasis (12 papers), Cancer, Hypoxia, and Metabolism (5 papers) and Cancer Genomics and Diagnostics (5 papers). Cheri A. Pasch collaborates with scholars based in United States, Canada and Japan. Cheri A. Pasch's co-authors include Dustin A. Deming, Linda Clipson, Kristina A. Matkowskyj, Susan N. Payne, Molly E. Maher, Melissa C. Skala, Alexander E. Yueh, Alyssa A. Leystra, William F. Dove and Karla Esbona and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Cheri A. Pasch

26 papers receiving 391 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cheri A. Pasch United States 11 203 166 125 74 59 31 397
Lotte Hiddingh United States 8 203 1.0× 214 1.3× 109 0.9× 40 0.5× 35 0.6× 9 523
Grace A. Hernandez United States 6 258 1.3× 282 1.7× 203 1.6× 32 0.4× 47 0.8× 11 664
Claudia Capdevila United States 6 165 0.8× 175 1.1× 148 1.2× 40 0.5× 29 0.5× 8 411
Victoria L. Bridgeman United Kingdom 9 233 1.1× 334 2.0× 132 1.1× 72 1.0× 13 0.2× 13 626
Sara Corvigno United States 13 228 1.1× 226 1.4× 146 1.2× 39 0.5× 19 0.3× 37 466
Yoshinari Shinsato Japan 14 164 0.8× 284 1.7× 129 1.0× 52 0.7× 22 0.4× 20 523
Oded Kopper Israel 7 284 1.4× 240 1.4× 132 1.1× 149 2.0× 16 0.3× 11 546
Sei Sai South Korea 12 137 0.7× 203 1.2× 128 1.0× 84 1.1× 17 0.3× 25 492
Anie Monast Canada 10 189 0.9× 290 1.7× 97 0.8× 23 0.3× 25 0.4× 10 566
Svetlana Miklikova Slovakia 12 168 0.8× 202 1.2× 117 0.9× 33 0.4× 25 0.4× 17 401

Countries citing papers authored by Cheri A. Pasch

Since Specialization
Citations

This map shows the geographic impact of Cheri A. Pasch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheri A. Pasch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheri A. Pasch more than expected).

Fields of papers citing papers by Cheri A. Pasch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheri A. Pasch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheri A. Pasch. The network helps show where Cheri A. Pasch may publish in the future.

Co-authorship network of co-authors of Cheri A. Pasch

This figure shows the co-authorship network connecting the top 25 collaborators of Cheri A. Pasch. A scholar is included among the top collaborators of Cheri A. Pasch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheri A. Pasch. Cheri A. Pasch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Emmerich, Philip B., Linda Clipson, Cheri A. Pasch, et al.. (2025). Stromal Versican Accumulation and Proteolysis Regulate the Infiltration of CD8+ T Cells in Breast Cancer. Cancers. 17(9). 1435–1435.
2.
3.
Wang, Ke, Xingchen Dong, Jonathan J. Sze, et al.. (2025). The Microbial Bile Acid Metabolite 3-Oxo-LCA Inhibits Colorectal Cancer Progression. Cancer Research. 85(24). 4937–4957.
4.
Pasch, Cheri A., et al.. (2025). Abstract 4316: Co-alterations in PIK3CA and ARID1A lead to greater sensitivity to PI3K pathway inhibition. Cancer Research. 85(8_Supplement_1). 4316–4316. 1 indexed citations
5.
Emmerich, Philip B., et al.. (2024). Cancer-Associated Fibroblast Proteins as Potential Targets against Colorectal Cancers. Cancers. 16(18). 3158–3158. 10 indexed citations
6.
7.
Deming, Dustin A., et al.. (2024). Abstract 1581: Colony-stimulating factor-1 receptor as a potential therapeutic target in pancreatic ductal adenocarcinoma. Cancer Research. 84(6_Supplement). 1581–1581. 1 indexed citations
8.
Pasch, Cheri A., et al.. (2024). Abstract 1952: Co-alterations in PIK3CA and ARID1A lead to enhanced sensitivity to PI3K inhibition. Cancer Research. 84(6_Supplement). 1952–1952. 1 indexed citations
9.
Dong, Xingchen, Fei Sun, Ke Wang, et al.. (2024). The dichotomous roles of microbial-modified bile acids 7-oxo-DCA and isoDCA in intestinal tumorigenesis. Proceedings of the National Academy of Sciences. 121(47). e2317596121–e2317596121. 5 indexed citations
10.
DeStefanis, Rebecca A., Jeremy D. Kratz, Amani A. Gillette, et al.. (2022). Impact of baseline culture conditions of cancer organoids when determining therapeutic response and tumor heterogeneity. Scientific Reports. 12(1). 5205–5205. 9 indexed citations
11.
Héninger, Erika, David Kosoff, Nan Sethakorn, et al.. (2021). Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling. Medical Oncology. 38(11). 135–135. 15 indexed citations
12.
Gillette, Amani A., Cheri A. Pasch, Linda Clipson, et al.. (2021). Autofluorescence Imaging of Treatment Response in Neuroendocrine Tumor Organoids. Cancers. 13(8). 1873–1873. 25 indexed citations
13.
Sharick, Joe T., Christine M. Walsh, Carley M. Sprackling, et al.. (2020). Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. Frontiers in Oncology. 10. 553–553. 96 indexed citations
14.
Emmerich, Philip B., Kristina A. Matkowskyj, Stephanie M. McGregor, et al.. (2020). VCAN accumulation and proteolysis as predictors of T lymphocyte-excluded and permissive tumor microenvironments.. Journal of Clinical Oncology. 38(15_suppl). 3127–3127. 4 indexed citations
15.
Payne, Susan N., Cheri A. Pasch, Linda Clipson, et al.. (2017). Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations. Molecular Cancer Research. 15(3). 317–327. 46 indexed citations
16.
Yueh, Alexander E., Susan N. Payne, Alyssa A. Leystra, et al.. (2016). Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K. PLoS ONE. 11(2). e0148730–e0148730. 16 indexed citations
17.
Clark, Paul A., et al.. (2016). The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells. Journal of Clinical Neuroscience. 36. 120–124. 40 indexed citations
18.
Leystra, Alyssa A., Terrah J. Paul Olson, Molly E. Maher, et al.. (2015). Colon Tumors with the Simultaneous Induction of Driver Mutations in APC , KRAS , and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence. Cancer Prevention Research. 8(10). 952–961. 20 indexed citations
19.
Payne, Susan N., Molly E. Maher, Nguyen H. Tran, et al.. (2015). PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. Oncogenesis. 4(10). e169–e169. 52 indexed citations
20.
Payne, Susan, Molly E. Maher, Nguyen H. Tran, et al.. (2015). Mutant PIK3CA-mediated pancreatic tumorigenesis and the response to PI3K pathway inhibition.. Journal of Clinical Oncology. 33(15_suppl). e15273–e15273.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lotte Hiddingh Breakdown of academic impact, for papers by Grace A. Hernandez Breakdown of academic impact, for papers by Claudia Capdevila Breakdown of academic impact, for papers by Victoria L. Bridgeman Breakdown of academic impact, for papers by Sara Corvigno Breakdown of academic impact, for papers by Yoshinari Shinsato Breakdown of academic impact, for papers by Oded Kopper Breakdown of academic impact, for papers by Sei Sai Breakdown of academic impact, for papers by Anie Monast Breakdown of academic impact, for papers by Svetlana Miklikova
Rankless by CCL
2026